CC-type chemokine receptor 5-Δ32 mutation protects against primary sclerosing cholangitis

Inflammatory Bowel Diseases

Volumn 12, Issue 4, 2006, Pages 272-277

  Henckaerts, Liesbet ^a,b   Fevery, Johan ^a   Van Steenbergen, Werner ^a   Verslype, Chris ^a   Yap, Paul ^a   Nevens, Frederik ^a   Roskams, Tania ^a   Libbrecht, Louis ^a,b   Rutgeerts, Paul ^a   Vermeire, Séverine ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

Author keywords

Disease susceptibility; Genetics; Sclerosing cholangitis

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; INTERNALIZATION; LIVER TRANSPLANTATION; LYMPHOCYTE HOMING; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MUTATION RATE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CHOLANGITIS, SCLEROSING; DNA; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTORS, CCR5;

EID: 33646817076     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000209790.21737.28     Document Type: Article

References (25)

1. Cullen S, Chapman R. Primary sclerosing cholangitis. Autoimmun Rev. 2003;2:305-312.
2. Feldstein AE, Perrault J, El Youssif M. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology. 2003;38:210-217.
3. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004;16:1201-1210.
4. Deng HK, Liu R, Ellmeier W. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661-666.
5. Liu R, Paxton WA, Choe S. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367-377.
6. Martinson JJ, Chapman NH, Rees DC. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet. 1997;16:100-103.
7. Lucotte G, Mercier G. Distribution of the CCR5 gene 32-bp deletion in Europe. J AIDS Hum Retrovirol. 1998;19:174-177.
8. Ashton LJ, Stewart GJ, Biti R. Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens. HIV Med. 2002;3:91-96.
9. Samson M, Libert F, Doranz BJ. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
10. Ribeiro S, Horuk R. The clinical potential of chemokine receptor antagonists. Pharmacol Ther. 2005;107:44-58.
11. Goulding C, Murphy A, MacDonald G. The CCR5-D32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut. 2005;54:1157-1161.
12. Wiesner RH, Larusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology. 1980;79:200-206.
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
14. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:3195-3199.
15. Rector A, Vermeire S, Thoelen I. Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Hum Genet. 2001;108:190-193.
16. Spurkland A, Saarinen S, Boberg KM. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens. 1999;53:459-469.
17. Wiencke K, Spurkland A, Schrumpf E. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology. 2001;34:625-630.
18. Van Steenbergen W, De Goede E, Emonds MP. Primary sclerosing cholangitis in two brothers: report of a family with special emphasis on molecular HLA and MICA genotyping. Eur J Gastroenterol Hepatol. 2005;17:767-771.
19. Neri TM, Cavestro GM, Seghini P. Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population. Dig Liver Dis. 2003;35:571-576.
20. Grant AJ, Lalor PF, Salmi M. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet. 2002;359:150-157.
21. Bittencourt PL, Palacios SA, Cancado EL. Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor alpha-308 promoter polymorphism. Gut. 2002;51:609-610.
22. Satsangi J, Jewell DP. CCR5delta32 polymorphism in inflammatory bowel disease: further association with ulcerative colitis and with primary sclerosing cholangitis. Gastroenterology. 2000;A337:2000.
23. Donaldson PT, Agarwal K, Saarinen S. Investigation of CCR5delta32 deletion and FAS/APO-I (CD95) single nucleotide polymorphisms in primary sclerosing cholangitis [abstract]. Hepatology. 2000 Oct;32:174A.
24. Eri R, Jonsson JR, Pandeya N. CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun. 2004;5:444-450.
25. Wiencke K, Louka AS, Spurkland A. Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients. J Hepatol. 2004;41:209-214.